Abstracts tagged "Pharmacoepidemiology"

Abstract Number: 2479 • ACR Convergence 2024
Mepolizumab Treatment Decreased Oral Corticosteroid Use and Improved Clinical Response, Control Status, and Remission in Patients with Eosinophilic Granulomatosis with Polyangiitis: Results up to 24 Months from a Large Network of US Allergy Practices
Michael E Wechsler¹, Anna Kovalszki², Jared Silver³, Brian Stone⁴, Lior Seluk⁵, Lynn Huynh⁶, Wilson da Costa Junior⁶, Mingchen Ye⁶, Jeremiah Hwee⁷, Mei Sheng Duh⁶, William McCann⁴ and Amy G. Edgecomb⁸, ¹Department of Medicine, National Jewish Health, Denver, CO, ²Division of Allergy and Clinical Immunology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, ³US Medical Affairs - Respiratory, GSK, Durham, ⁴Allergy Partners, Asheville, NC, ⁵Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, ⁶Analysis Group, Boston, MA, ⁷Value Evidence and Outcomes, GSK, Mississauga, Canada, ⁸US Value, Evidence, & Outcomes, Anti-Infectives and Respiratory, GSK, Philadelphia
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a severe rare systemic inflammatory disease characterized by elevated blood eosinophil counts ≥1000 cells/µL and vasculitis of small-…
Abstract Number: 1005 • ACR Convergence 2024
Pharmacosurvellience Study of FDA Adverse Event Reporting System (FAERS) Events of Tofacitinib and Upadacitinib
Nur Barlas, Sait Barlas, Stefan Milutinovic and Shristi Basnyat, Florida State University College of Medicine Internal Medicine Residency Program at Lee Health, Cape Coral
Background/Purpose: Janus Kinase (JAK) inhibitors are the agents of choice for the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis when other DMARDs are…
Abstract Number: 2566 • ACR Convergence 2024
Detrimental Effects of Proton Pump Inhibitors on Bone Mineral Density Are Not Mediated by Changes in Serum Calcium or Parathyroid Hormone in Patients with Inflammatory Rheumatic Diseases: A Cross-sectional Study
andriko Palmowski¹, Zhivana Boydzhieva², Paula Hoff³, Sandra Hermann³, burkhard Muche³, David Simon⁴, Gerhard Krönke³, Edgar Wiebe⁵ and FRANK HARTMUT DR. BUTTGEREIT⁵, ¹Charité - Universittsmedizin Berlin, Berlin, Germany, ²Charité Universittsmedizin, Berlin, Germany, ³Rheumatology, Charité, Berlin, Germany, ⁴Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany/ Department of Internal Medicine 3, University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany/Deutsches Zentrum für Immuntherapie (DZI), University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Berlin, Germany, ⁵Charité University Medicine Berlin, Berlin, Germany
Background/Purpose: In a previous study, we found daily proton pump inhibitor (PPI) intake to be associated with decreased bone mineral density in patients with inflammatory…
Abstract Number: 1049 • ACR Convergence 2024
Very Low Uptake of Biosimilar Adalimumab in the First 9 Months of Availability in Rheumatology
Eric Roberts¹, Gabriela Schmajuk² and Jinoos Yazdany³, ¹University of California, San Francisco, SF, CA, ²UCSF / SFVA, San Francisco, CA, ³UCSF, San Francisco, CA
Background/Purpose: In 2021, over 300,000 patients in the United States used adalimumab, making it one of the highest-grossing drugs globally. In 2023, patent exclusivity for…
Abstract Number: 2609 • ACR Convergence 2024
Drivers of Infliximab Biosimilar Uptake: A Comparative Analysis of New Biosimilar Initiations versus Switching in a National Rheumatology Registry
Eric Roberts¹, Nick Bansback², Chien-Wen Tseng³, Steve Shiboski⁴, Jing Li⁵, Gabriela Schmajuk⁶ and Jinoos Yazdany⁷, ¹University of California, San Francisco, SF, CA, ²University of British Columbia, Vancouver, BC, Canada, ³University of Hawai'i John A. Burns School of Medicine, Honolulu, ⁴University of California, San Francisco, San Francisco, ⁵University of California, San Francisco, San Francisco, CA, ⁶UCSF / SFVA, San Francisco, CA, ⁷UCSF, San Francisco, CA
Background/Purpose: Biosimilars hold promise for reducing pharmaceutical expenditures, however uptake has lagged. We analyzed the variability in new biosimilar starts and switching from bio-originator infliximab…
Abstract Number: 1073 • ACR Convergence 2024
Dashboard Utilization and Order Menu Revision Improve HLA-B*5801 Testing Prior to Allopurinol Initiation in High-Risk Patients in a Veteran-based Primary Care Setting
Catherine Vo, Chialin Nguyen, Scott Hagan, Sheida Aalami and Elizabeth Wahl, VA Puget Sound Healthcare System, Seattle, WA
Background/Purpose: The 2020 ACR Guideline for the Management of Gout conditionally recommends testing for the HLA-B*5801 risk allele prior to starting allopurinol for patients of…
Abstract Number: 1189 • ACR Convergence 2024
Certain Dosages of Fasinumab Provides Superior Benefits over Placebo in Mitigating Osteoarthritis Symptoms Albeit at Increased Health Detriments: A Systematic Review and Meta-Analysis
Muhammad Sohaib Khan¹, Wania Moeen², Umm E Salma Shabbar Banatwala², Muhammad Usman², Umar Mahmood², Syed Ashad Ahmed Fatmi², Syed Muhammad Muneeb Akhtar², Hania Shahzad³, Muhammad Talal Ibrahim⁴, Nisar Ahmed⁵, Badaruddin Sahito² and Muhammad Sohaib Asghar⁶, ¹Dow University of Health Sciences, Karachi, Pakistan, ²Dow University of Health Sciences, Karachi, Sindh, Pakistan, ³UC Davis Health, Sacramento, CA, ⁴The Ohio State University Wexner Medical Center, Columbus, OH, ⁵Rapido’s Clinica Familiar, Chicago, ⁶AdventHealth, Sebring, FL
Background/Purpose: Fasinumab, a newly developed anti-nerve growth factor monoclonal antibody, is currently under investigation for its potential to alleviate symptoms in osteoarthritis patients. This meta-analysis…
Abstract Number: 1214 • ACR Convergence 2024
All-Cause Mortality in Patients with Chronic Musculoskeletal Pain Using Pregabalin or Duloxetine: A Retrospective Cohort Study in US Veterans
Sachalee Campbell¹, Laura L. Daniel², Alyson L. Dickson³, Otis Wilson³, C. Michael Stein³, Puran Nepal⁴, Adriana M. Hung⁵ and Cecilia P. Chung², ¹University of Miami/ Jackson Health System, Miami, FL, ²University of Miami, Miami, FL, ³Vanderbilt University Medical Center, Nashville, TN, ⁴Vanderbilt University Medical Center, Vanderbilt, TN, ⁵Veterans Administration Tennessee Valley Healthcare System, Nashville, TN
Background/Purpose: Musculoskeletal pain affects more than 10% of the general population. Recent trends in managing chronic musculoskeletal pain have favored non-opioid analgesics, for example, pregabalin,…
Abstract Number: 1215 • ACR Convergence 2024
Mortality in US Veterans with Musculoskeletal Conditions Using Cyclobenzaprine or Baclofen
Maria Intriago¹, Puran Nepal², Laura L. Daniel¹, Alyson L. Dickson³, Otis Wilson³, C. Michael Stein³, Adriana M. Hung⁴ and Cecilia P. Chung¹, ¹University of Miami, Miami, FL, ²Vanderbilt University Medical Center, Vanderbilt, TN, ³Vanderbilt University Medical Center, Nashville, TN, ⁴Veterans Administration Tennessee Valley Healthcare System, Nashville, TN
Background/Purpose: Cyclobenzaprine is a commonly-used centrally-acting muscle relaxant; it has been approved for short-term treatment of muscle spasms associated with acute musculoskeletal pain despite limited…
Abstract Number: 0152 • ACR Convergence 2024
Hydroxychloroquine and Chloroquine Retinopathy in Hispanic Patients with Rheumatic Diseases
Janett Riega Torres¹, Karina Palomo-Arnaud², Gabriel Figueroa-Parra¹, Fernando Morales Wong¹, Jesús Hernán González Cortés¹, Jesus Mohamed Hamsho¹, Jorge Esquivel-Valerio¹, Dionicio Galarza-Delgado³ and Karim Mohamed Noriega¹, ¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ²Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, San Nicolás de los Garza, Mexico, ³UANL Hospital Universitario, Monterrey, Nuevo León, Mexico
Background/Purpose: Antimalarial drugs like hydroxychloroquine (HCQ) and chloroquine (CQ) are among the most frequently prescribed medications in Rheumatology. Retinal toxicity is an unwanted side effect…
Abstract Number: 1270 • ACR Convergence 2024
Association of Disease-Modifying Anti-Rheumatic Drug Selection with Hospitalized Infection in Youth with Childhood-Onset Systemic Lupus Erythematosus
Jordan Roberts¹, Anna Faino², Marshall Brown³, Gabrielle Alonzi⁴, Mersine Bryan⁵, Cordelia Burn⁶, Joyce Chang⁴, Jonathan Cogen⁷, Nidhi Naik⁸, Kareena Patel⁹, Emily Zhang⁴, Mary Beth Son¹⁰ and Esi Morgan¹, ¹Seattle Children's Hospital, Seattle, WA, ²Seattle Children's Research Institute, Core for Biostatistics, Epidemiology and Analytics in Research, Seattle, ³Core for Biostatistics, Epidemiology and Analytics in Research, Seattle Children's Research Institute, Seattle, WA, ⁴Boston Children's Hospital, Boston, MA, ⁵Division of Hospital Medicine, Seattle Children's Hospital, Seattle, WA, ⁶Seattle Children's Hospital, Boston Children's Hospital, Seattle, ⁷Seattle Children’s Hospital, Seattle, WA, ⁸Seattle children's hospital, Bothell, WA, ⁹Seattle Children's Hospital, Seattle, ¹⁰Boston Children's Hospital, Brookline, MA
Background/Purpose: Youth with childhood-onset systemic lupus erythematosus (cSLE) have increased risk of serious infection. It is unknown how much of this risk is due to…
Abstract Number: 0159 • ACR Convergence 2024
Prevalence and Potential Factors Associated with Polypharmacy in Individuals with Systemic Lupus Erythematosus
Jianing Yang¹, Jinoos Yazdany², S. Sam Lim³, Brad Pearce³ and Laura Plantinga⁴, ¹Highland Hospital, AHS, San Leandro, CA, ²UCSF, San Francisco, CA, ³Emory University, Atlanta, GA, ⁴University of California, San Francisco, San Francisco, CA
Background/Purpose: Polypharmacy is associated with an increased risk of adverse drug effects and medication nonadherence. However, the prevalence of polypharmacy and the medications and factors…
Abstract Number: 1439 • ACR Convergence 2024
Risk of Hip and Spine Fractures in Axial Spondyloarthritis Is Associated with Treatment Class
Devin Driscoll¹, Navya George², S. Reza Jafarzadeh³, Christine Peloquin³, Jean Liew³ and Maureen Dubreuil⁴, ¹Boston Medical Center, Boston, MA, ²Boston University Medical Center Internal Medicine Residency Program, Boston, MA, ³Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁴Section of Rheumatology, Boston University School of Medicine, Boston, MA
Background/Purpose: Individuals with axial spondyloarthritis (axSpA) have a risk of fracture that is nearly double that of the general population, possibly related to chronic inflammation.…
Abstract Number: 1340 • ACR Convergence 2023
Recent Trends in Treatment Patterns for Rheumatoid Arthritis in Response to Emerging Data
Stephanie Song¹, Michael George², Ted R Mikuls³, Bryant England⁴, Brian Sauer⁵, Grant Cannon⁶ and Joshua Baker², ¹Hospital of the University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶University of Utah and Salt Lake City VA, Salt Lake City, UT
Background/Purpose: Janus kinase inhibitors (JAKi) have demonstrated substantial efficacy in decreasing symptoms and in reducing progressive joint damage in patients with rheumatoid arthritis (RA). In…
Abstract Number: 1386 • ACR Convergence 2023
Opioid Prescription Rates in Patients with Ankylosing Spondylitis in the UK Between 2001-2020: An Electronic Health Records (EHR) Analysis
Huseyin Berk Degirmenci¹, Christine E. Peloquin², Sara Lodi², Pedro Machado³, S. Reza Jafarzadeh⁴, Tuhina Neogi⁵, Lianne Gensler⁶, Maureen Dubreuil⁷ and Jean Liew², ¹St. Elizabeth's Medical Center, Boston, MA, ²Boston University, Boston, MA, ³Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK. Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS trust, London, UK., London, United Kingdom, ⁴Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁵Boston University School of Medicine, Boston, MA, ⁶University of California San Francisco, Department of Medicine, Division of Rheumatology, San Francisco, CA, ⁷Department of Rheumatology, Boston University School of Medicine, Milton, MA
Background/Purpose: Although current axial spondyloarthritis (axSpA) management guidelines do not address opioid use for chronic pain, available data show that opioid use is common among…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].